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Background: Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease as well as Lou Gehrig’s
disease, is a progressive neurological disorder selectively affecting motor neurons with no currently known
cure. Around 20% of the familial ALS cases arise from dominant mutations in the sod1 gene encoding super-
oxide dismutase1 (SOD1) enzyme. Aggregation of mutant SOD1 in familial cases and of wild-type SOD1 in at
least some sporadic ALS cases is one of the known causes of the disease. Riluzole, approved in 1995 and edar-
avone in 2017 remain the only drugs with limited therapeutic benefits.
Methods:We have utilised the ebselen template to develop novel compounds that redeem stability of mutant
SOD1 dimer and prevent aggregation. Binding modes of compounds have been visualised by crystallography.
In vitro neuroprotection and toxicity of lead compounds have been performed in mouse neuronal cells and
disease onset delay of ebselen has been demonstrated in transgenic ALS mice model.
Finding:We have developed a number of ebselen-based compounds with improvements in A4V SOD1 stabili-
sation and in vitro therapeutic effects with significantly better potency than edaravone. Structure-activity
relationship of hits has been guided by high resolution structures of ligand-bound A4V SOD1. We also show
clear disease onset delay of ebselen in transgenic ALS mice model holding encouraging promise for potential
therapeutic compounds.
Interpretation: Our finding established the new generation of organo-selenium compounds with better in
vitro neuroprotective activity than edaravone. The potential of this class of compounds may offer an alterna-
tive therapeutic agent for ALS treatment. The ability of these compounds to target cysteine 111 in SOD may
have wider therapeutic applications targeting cysteines of enzymes involved in pathogenic and viral diseases
including main protease of SARS-Cov-2 (COVID-19).
Funding: Project funding was supported by the ALS Association grant (WA1128) and Fostering Joint Interna-
tional Research (19KK0214) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT),
Japan.
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Amyotrophic lateral sclerosis (ALS), also referred to as motor neu-
ron disease (MND) and Lou Gehrig’s disease, occurs in approximately
2 per 100,000 individuals worldwide, causing loss of motor neurons
in the cerebral cortex and spinal cord resulting in severe muscleweakness, paralysis and fatal respiratory failure within 25 years
from disease onset [1]. For some sporadic (sALS) and twenty percent
of the familial (fALS) cases, the disease has its origins in superoxide
dismutase whose stability as a dimer is compromised leading to a
‘gain of function’ that results in aggregation of protein [2]. Among the
25 genes contributing to fALS [1], genetic defect in sod1 located on
chromosome 21q22.11 was the first one to be discovered and is thus
best studied with over 180 different known mutations [3], some of
which are more common in certain populations. In North America,
half of sod1-related fALS cases arise from mutation of Ala4 to Val [4],
with one of the most severe forms of fALS with the shortest survival
Research in Context
Evidence before this study
Toxic inclusion of superoxide dismutase 1 (SOD1) mutant in
neuron cells is one of the causes of Amyotrophic lateral sclero-
sis (ALS), a progressive neurological disorder. There are only
two approved drugs, riluzole and edaravone, for ALS treatment
with limited effectiveness. Discovery and developmentt of new
drugs is urgently needed for ALS patients. Ebselen, a synthetic
organo-selenium drug with potent anti-oxidant and cytopro-
tective effects, is considered to be a potential template for
developing therapeutic molecules that can stabilise dimers of
ALS-causing SOD1 mutant via binding to cysteine 111 which
could reduce aggregation and delay disease progression.
Added value of this study
In this work, we established a group of organo-selenium com-
pounds using benzoisoselenazolone warhead of ebselen with
potent SOD1 mutant stabilisation effect. We elucidated binding
modes of compounds at the dimer interface of SOD1 mutant by
high resolution crystal structures which are beneficial for
describing structure-activity relationship. Some of these com-
pounds exhibited better in vitro neuroprotection in mouse neu-
ronal cells than edaravone. In vivo disease onset delay by
ebselen has been demonstrated for the first time in transgenic
ALS mice model.
Implications of all the available evidence
Our findings suggest ebselen-based compounds are a valuable
class of ALS therapeutic agents with superior in vitro neuropro-
tection than edaravone and with acceptable safety characteris-
tics. In vivo disease onset delay of ebselen also strengthens the
potential of ebselen-based compound to be progressed to next
stage of drug development programme with potential for ther-
apies that could be offered to patients as alternative treatments
alone or in combination with other approved ALS drugs in
future.
2 K. Amporndanai et al. / EBioMedicine 59 (2020) 102980time [5]. To date, there are only two drugs approved for clinical use in
ALS patients: riluzole and edaravone [6]. Riluzole modestly extends life
expectancy by 23 months in the final stage of ALS but has poor posi-
tive effect at earlier stages of the disease [7]. Edaravone has had limited
success and acceptance as a drug worldwide but is more effective than
riluzole in slowing disease progression, with a limited application
requiring daily intravenous infusion [8]. Hence, extensive research
efforts continue globally in search for convenient and affordable new
drugs that increase survival time with minimal adverse effect.
The copper- and zinc-containing superoxide dismutase 1 (SOD1)
possesses four cysteine residues. The active and stable SOD1 is a
homodimer stabilised by an intramolecular disulphide bond between
cys57 and cys146 and metal sites bridged by histidine residues that
are loaded with Cu and Zn [9]. SOD1 possesses two additional free
cysteine residues cys6 and cys111, is mostly distributed in cytoplasm
and is responsible for converting toxic reactive superoxide into oxy-
gen and hydrogen peroxide preventing oxidative stress within the
cells [10]. Extensive efforts have established that it is not the func-
tional loss of SOD’s enzymatic activity that is responsible for the ALS
causing properties [11], but destabilisation of dimer caused by muta-
tions or loss of metals in the metal site that leads to aggregation prop-
erties which are the disease causing agents [9,12]. Moreover, ALS-
causing mutants including A4V have been found to heterodimerise
with wild-type SOD1 and exert higher accumulation of toxic SOD1aggregates in cell and animal models [13,14]. Several small molecules
have shown stabilising effect on SOD1 dimer and diminished inclu-
sions which could delay the development of ALS [1517]. One of the
binding sites within SOD1 structure focused as a drug target is
cys111, which is a solvent-exposed residue at the dimer interface
that is vulnerable to oxidative modification giving rise to aggregation
[18,19]. Chemical cross-linking between subunits at cys111 using
maleimide-based compound has been proven to be a good strategy
to promote thermal stability of G93A and G85R SOD1 [15]. Repurpos-
ing chemotherapeutic agent of cisplatin for curing neurodegenerative
disease also raises SOD1 dimer stability and inhibits oligomerisation
of metal-free SOD1 [16]. However, both compounds could not be
developed further since the steric hindrance imposed by drug protein
adduct formation negatively influences the interaction of SOD1 with
human copper chaperone (hCCS) resulting in the disruption of SOD1
maturation with resultant toxicity [20].
Ebselen is an organo-selenium compound that scavenges reactive
oxygen species and enhances cellular defence from oxidative damage
[21]. Neuroprotective actions of ebselen in rodent models have been
observed in several reports [2224]. Notably in proteomics studies,
ebselen can compromise the cellular toxic effect in mitochondria
induced by the expression of ALS-related SOD1 mutant [25]. Further-
more, ebselen exhibits covalent binding at cys111 without impeding
interaction between SOD1 and hCCS indicating greater potential over
other compounds to be developed as an effective neuroprotective
drug [17].
In our recent work, differential scanning fluorescence (DSF) assay
has been introduced as a medium-throughput screen for ebselen and
some potential derivatives that promote SOD1 thermal stability [26].
Here, we have developed next generation ebselen derivatives based
on the compounds previously published with improved SOD1 dimer
stabilising effect and drug-like properties. A new higher diffracting
form of small molecule-bound A4V SOD1 crystals has been estab-
lished allowing us to visualise ligand pose of the compounds target-
ing cys111 in the pathogenic target enabling lead optimisation
through structure-based approaches. Furthermore, ebselen and our
potent derivatives were investigated for neuroprotective effects in in
vitro and in vivo models. Some compounds at nanomolar concentra-
tion have been demonstrated to redeem in vitro viability of mouse
neuron cells expressing pathogenic SOD1 including A4V mutant up
to similar level of the wild-type SOD1 counterpart. We show that
ebselen clearly replicates neuroprotective activity in vivo by delaying
disease onset in G93A SOD1 transgenic mice, which is the representa-
tive mouse model for SOD1-linked ALS [27].
2. Materials and methods
2.1. Ethics statement
The experiments using genetically modified animals and organ-
isms were approved by the Animal Care and Use Committee and the
recombinant DNA experiment committee of Nagoya University
(approval numbers #19269 and #143, respectively). The mice were
treated in compliance with ARRIVE guideline and the animal
use guidelines of the Animal Care and Use Committee, Nagoya
University.
2.2. Synthesis of lead compounds
Details for the synthesis of ebselen analogues are included in the
supplementary information.
2.3. Recombinant SOD1 production
The pET303C plasmids containing A4V and double-point mutated
A4V C6S human SOD1 genes were generated by site-directed
K. Amporndanai et al. / EBioMedicine 59 (2020) 102980 3mutagenesis from wild-type gene using primers shown in Table S1
and transformed into E. coli strain BL21(DE3). The SOD1 transform-
ants were cultured at 37 °C in ampicillin-supplemented LB broth until
optical density at 600 nm reaches 0.60.8. Then, SOD1 expression
was induced by the addition of 0.5mM Isopropyl b-d-1-thiogalacto-
pyranoside (IPTG) and 0.3mM ZnSO4 followed by incubation at 18°C
for 16 hours. Recombinant proteins were purified by two different
methods previously described [28]. A4VC6S SOD1 mutant used in DSF
assays was purified using anion-exchange chromatography on dieth-
ylaminoethanol (DEAE) sepharose and eluted in a stepwise increasing
concentration of NaCl. Protein fractions eluted in 5100mM NaCl
were combined and loaded to a Superdex 200 16/600 column (GE
Healthcare) in Tris-buffered saline (TBS) pH 7.4. Recombinant A4V
SOD1 used in crystallographic study was purified by precipitation cut
using 2.5M ammonium sulphate followed by hydrophobic interaction
chromatography on Phenyl sepharose (GE Healthcare) eluted in a
stepwise decreasing concentration of ammonium sulphate. A4V
SOD1 obtained in 1-2M ammonium sulphate fractions were dialysed
against Tris-buffered saline (TBS) pH 7.4 at 4 °C overnight followed
by gel filtration on a Superdex 200 16/600 column (GE Healthcare)
eluted with the same buffer. The purified proteins were snap-frozen
in liquid nitrogen and stored at 80 °C prior to experiments. The con-
centration of all SOD1 proteins was determined by ultraviolet absorp-
tion at 280nm using a molar extinction of 5500M1cm1.2.4. Differential scanning fluorimetry (DSF)
All DSF experiments were carried out using a StepOnePlus Real-
Time PCR machine (Life Technologies). 100 mM A4VC6S SOD1 was
pre-incubated with 500 mM compounds diluted from 250mM stock
solution at 4°C overnight. The mixtures were buffer-exchanged
against fresh TBS using micro-centrifugal ultrafilter (Vivaspin, MWCO
5kDa) to remove excess compound. 70 mM buffer-exchanged protein
was mixed with 10 £ concentration of SYPRO Orange dye (Life Tech-
nologies) which was used as a fluorescent probe. Fluorescent intensi-
ties were monitored from 25 °C to 95 °C at a ramp rate of 0.3 °C/min.
The melting temperature (Tm) was calculated based on the Boltz-
mann equation using the Tm ToolTM software (Life Technologies)2.5. Crystallisation and structure determination
All compounds were prepared for 250mM stock solution by dis-
solving in DMSO. 0.2mM of A4V SOD1 was incubated with 1mM com-
pound being at 4 °C overnight before concentrated to 10mg/mL
SOD1. 3 mL of A4V SOD1 solution was set hanging crystallisation
drops by mixing with 3 mL of reservoir solution containing 100mM
sodium acetate pH 4.7, 150mM NaCl and 2.52.8M ammonium sul-
phate. The crystallisation drops were incubated at 19°C for 2-3 days
allowing vapour diffusion against corresponding reservoir solutions
before macro-seeding using a few A4V SOD1 crystals in P21 space
group previously grown in the same condition. Mature crystals were
obtained within a week after seeding and soaked in Paratone oil
(Hampton Research) as cryo-protectant before freezing in liquid
nitrogen. Diffraction data was collected at 100K on I03 (compounds
3, 6 and 9), I04 (compounds 1 and 5), I04-1 (ebselen, compounds 2
and 10) and I24 (compound 13) at Diamond Light Source, UK, inte-
grated using DIALS [29] and scaled using Aimless [30] in CCP4 suite.
Phase problem of all structures was solved by molecular replacement
using an A4V SOD1 structure (PDB: 1UXM; chain A and B) as a start-
ing model in MolRep [31]. Structure models were initially refined by
rigid body refinement in Refmac5 [32] and then manually modified
in COOT [33] followed by cycles of restrained refinement in Refmac5.
Ligand models of ebselen-based compounds were produced in Jli-
gand [34] and manually added into corresponding electron density.2.6. Cell culture, transfection and MTS assay
Mouse neuroblastoma Neuro2a cells (RRID: CVCL_0470) were cul-
tured and measured their viability as described previously [35].
Briefly, the cells seeded at 5.0 £ 103 /well on a poly-D-lysine coated
96 well plate were transfected to express mutant human SOD1 spe-
cies using Lipofectamine 2000 (Thermo Fisher Scientific). After 6 h of
transfection, the growth medium (Dulbecco's Modified Eagles'
Medium (DMEM) containing 4.0 g/L glucose, 10 %(v/v) fetal bovine
serum (FBS) (both from Thermo Fisher Scientific)) was replaced with
a differentiation medium (DMEM containing 1.0 g/L glucose, 2 %(v/v)
FBS and 2 mM N6,20-O-dibutyryladenosine 30,50-cyclic monophos-
phate (Nacalai Tesque, Kyoto, Japan)) with the indicated ebselen-
derived compounds at the indicated concentration. All the com-
pounds were first dissolved into DMSO at 10 mM and stored at -30 °C
until use. The cells were incubated for 48 h, and the differentiation
medium was replaced with a fresh one. Then, the cell viability was
measured using MTS assay (CellTiter 96 AQueous One Solution Cell
Proliferation Assay, #G3580, Promega Biosciences, San Louis Obispo,
CA, USA) according to the manufacturer’s instructions with an
absorption spectrophotometer Infinite F50R (TECAN Group Ltd.,
M€annedorf, Switzerland). To determine LC50 of the compounds, the
cell viability at different compound concentrations was fitted using
the least squares method to a sigmoid curve with the following for-




Transgenic mice expressing SOD1G93A (B6.CgTg(SOD1*G93A)
1Gur/J) (RRID: IMSR_JAX:004435) were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). Genotyping for the SOD1G93A mice
and determination of the times for disease onset and end-stage were
previously described [36]. In brief, the disease onset was determined
by the time when the mice reached maximal body weight. The mice
were randomly divided into two groups that fed with a powdered
CE-2 diet (CLEA Japan Inc., Tokyo, Japan) in the presence or absence
of 0.016 % ebselen (#E0946, Tokyo Chemical Industry Co., Ltd., Tokyo,
Japan) using a feeder for powder diet provided by Shinano Seisa-
kusho Inc. (#SN-950) (Tokyo, Japan) from 70 days of age to the end-
stage. The diet was replenished three times per week, and the mice
had free access to their assigned diet and deionized water. We esti-
mated the amount of ebselen taken by mice from the food intake,
and confirmed that about 300 mg/kg/day ebselen was taken during
all over the cohort. The mice were housed in the specific pathogen-
free (SPF) environment (with a 12 h lightdark cycle at 23 § 1°C)
and treated in compliance with the requirements of the Animal Care
and Use Committee, Nagoya University.
2.8. Statistics
For animal experiments, G93A SOD1 mice were grouped in a ran-
dom manner. Measurements of motor function and body weights
were carried out in a non-blinded manner. Survival times were ana-
lyzed with a log-rank test, and no sample size calculation was per-
formed in this study. All the data of MTS assays were analyzed by
one-way ANOVA followed by the post-hoc Tukey’s multiple compari-
son t-test. All the statistical analyses were carried out by using
GraphPad Prism 8 software (GraphPad Software, La Jolla, CA).
2.9. Role of funding source
Compound synthesis, DSF screen and crystallography were sup-
ported by the ALS Association grant (WA1128). Cell-based and animal
model studies were granted by Fostering Joint International Research
(19KK0214) from the Ministry of Education, Culture, Sports, Science
and Technology (MEXT), Japan. Funders did not play any part in study
4 K. Amporndanai et al. / EBioMedicine 59 (2020) 102980design, data collection, data analyses, interpretation, or writing of the
manuscript.3. Results
3.1. Generation of novel ebselen analogues with good physicochemical
properties that promote SOD1 thermal stability
Ebselen has been demonstrated to bind cys111 and stabilise dimer
of A4V SOD1, which is severely prone to monomerise and aggregate
leading to acute form of ALS [17,26]. Based on benzoisoselenazolone
core of ebselen, functionalised N-aryl and methylene linker moieties
were incorporated into the organoselenium core to improve dimer
stabilisation of SOD1 and drug-like properties (Figure S1). To rank sta-
bilising effect of ebselen-based small molecules, DSF screen against
A4V SOD1 with C6S mutation background (A4VC6S SOD1) has been
used to evaluate performance via different melting temperatures of
compound-treated and native protein (ΔTm). C6S background was
designed to eliminate the destabilisation of A4V SOD1 in solution due
to occasional binding of ebselen to free thiol of cys6 which results in
undeterminable melting curve of DSF assay [26]. A greater positive
ΔTm indicates improved thermal stability of A4VC6S SOD1 affected by
compound binding. The compounds with a methylene linker
imparted greater thermal stability than N-aryl derivatives. The struc-
tures of A4V SOD1 bound with ebselen and its methylene linked
derivative (compound 2) derived from C2 space group crystals reveal
distinct binding poses of ligands (Figure S2), which could describe dif-
ferent outcomes in ΔTm values. Ebselen, an N-aryl compound, inter-
acts with loop VI of SOD1 (residues 101-109), whilst compound 2
poses perpendicularly to ebselen placing its aromatic tail into the gap
between Thr2 and Ile151. Therefore, functionalising the aryl ring of
the methylene linker scaffold that enables further interactions may
provide better stabilisation of SOD1 dimer. This offers greater sub-
strate scope to be incorporated into the methylene linker series com-
pared to the N-aryl scaffold analogues [26].
Herein, a series of methylene linker (compounds 110 and 14)
and N-aryl (compounds 1113) compounds incorporating a variety
of functional groups were synthesised and their ΔTm values in A4VC6S
SOD1 were measured by DSF assays. Compounds 1,3 and 9 have
stronger stabilising effect on A4VC6S SOD1 above other methylene
linked compounds as shown in Table 1. Furthermore, incorporation
of a carbonyl morpholine moiety with benzoisoselenazolone core
(compounds 1214) seems to establish outstanding ΔTm values at
the same level or better than ebselen. Apart from increasing stability
of SOD1 dimer, potent candidates need to have suitable drug-like
properties that allow central nervous system (CNS) access and desir-
able absorption, distribution, metabolism and excretion (ADME) pro-
files. These parameters can be predicted and ranked by multi-
parameter optimisation (MPO) score using an algorithm developed
by Pfizer [37]. The following physicochemical aspects are accounted
to address specific ADME properties to ensure the compound is CNS
penetrable based on known CNS drugs and potential candidates
along with a diverse range of Pfizer compounds. MPO scores range
from 0 to 6.0, and the values 4.0 represent likelihood of compounds
to reach CNS drug target. Figure S3 shows the map of desirable ranges
for each physicochemical parameter of the MPO scoring algorithm.
Each parameter is given defined limits and if any parameter is found
outside the defined limits then a penalty is given to each specific
parameter which dictates the overall MPO score. All MPO scores and
other calculated physicochemical parameters of each compounds are
given in Tables 1 and 2 and highlighted how good or bad in traffic
light system. It can be clearly seen that the compounds with high
ΔTm values, particularly compounds 3, 6, 914, possess desirable
ranges of MPO scores and other parameters, qualifying them for tests
in cellular and animal models.3.2. Direct visualisation of binding modes of compounds in A4V SOD1
A4V SOD1 crystals in the recently obtained high resolution form
in the P21 space group enabled determination of several ligand-
bound A4V SOD1 structures to a resolution range of 1.30-1.95A

depending on the compound and showing details of binding mode of
these compounds at cys111. Crystallographic data collection and
refinement statistics of P21 crystals of A4V SOD1 with ebselen and
eight derivatives are presented in Table 3. There is only one SOD1
dimer in asymmetric unit of P21 crystals. Electron density maps of
the ligands in this crystal form are clearly visible between dimer
interface and able to be modelled unambiguously as shown in Fig. 1.
With higher resolution diffraction of P21 crystals, we can observe
electron density of water molecules around the ligand, which is an
advantage for investigating water bridge formation between ligand
and amino acids that could rationalise how some compounds pro-
mote ΔTm of SOD1. All co-crystallised compounds in P21 space group
also show that the direction of aromatic tail of each compound
depends on its scaffold. Ebselen which is a N-aryl compound appears
to pose their aromatic tail jutting out to the solvent space along Loop
VI of SOD1, while compound 1 which contains methylene linker is
placed perpendicularly to Loop VI and contacted with N- and C-ter-
mini at Thr2 and Ile151, respectively (Fig. S4). For other compounds
in each scaffold, the overall ligand poses with the same scaffold are
mostly similar to either ebselen or compound 1.
In crystal structures of A4V SOD1ebselen, N-aryl compound 13
(Fig. 2a), we clearly observe p-p stacking between aromatic rings of
these compounds. The overlaid structures in Fig. 2a show that fluori-
nated seleno-head group of the compound 13 has an identical pose
to ebselen, so incorporation with fluorine atom does not change the
binding pose. Notably, the carbonyl morpholine moiety and fluorine
atom in compound 13 can establish few hydrogen bonds with water
molecules bridging between protein and ligand (Figs. 1a). These
interactions explain the rationale behind greater ΔTm of compound
13 above ebselen and could be utilised as the template for future lead
optimisation. For the compounds with a methylene linker, we have
successfully co-crystallised six of this class of compounds giving good
opportunity to see the influence of Cl and OMe substituents on the
phenyl or pyridyl tail group. Starting with chlorobenzyl ebselens,
compounds 2 and 5 have a highly similar ligand pose observed in
overlaid crystal structures in Fig. 2b. Unlike N-aryl compounds, A4V
SOD1-compounds 2 and 5 structures display longer distance between
seleno-aromatic rings (Fig. 2b). Thus, the interaction between com-
pounds is weaker than N-aryl compounds. Moreover,meta-Cl substit-
uent shifts the benzyl group away from Thr2 and Ile151 impairing
hydrophobic contacts between N- and C- termini (Fig. 2b). This may
cause weaker SOD1 stability of compound 5 than compound 2. In the
superimposed structures of A4V SOD1-compounds 3 and 6, only one
monomer appears perfectly overlaid compound molecules like com-
pounds 2 and 5 (Fig. 2c). Compound 6 at another monomer acts as a
bridge between monomers by localisation of itsmeta-methoxybenzyl
tail closer to the main chain of Asp109 of another monomer, while
compound 3 behaves identically to compounds 1, 2 and 5 whose tail
picks up hydrophobic interactions with Thr2 and Ile151. Cross-mono-
mer interaction of compound 6 seems to enhance dimer interface
whereas ΔTm of compound 6 is lower than compounds 1 and 3, which
have closer contact to N- and C-termini (Fig. 2c). This indicates that
the interaction between Thr2 and Ile151 is probably more important
for dimer stability than the interaction between benzyl tail and
neighbour Asp109. On the other hand, this concept is not applicable
to compounds 9 and 10 that pyridyl or para-methoxypyridyl rings
were replaced in the scaffold of compound 1. Strong stabilising pro-
file was observed in both compounds, especially compound 9 with
greater DTm than ebselen. The binding pose of compound 9 appears
in the same way as compound 6 but compound 10 performs similarly
to compound 3 (Fig. 2d). This contrasting effect may occur because
Table 1
Methylene linker series compounds 1-10with their A4VC6S SOD1 dimer stability (DTm), MPO score and each physicochemical parameter that contributes to
the overall score. 1-3 are from [26]. A traffic light system was employed to demonstrate each value contribution; Green  good/desirable; Amber  ok; Red
 poor/undesirable. ClogP: calculated logarithm of partition coefficient of a compound between n-octanol and water, ClogD: calculated logarithm of distri-
bution coefficient of a compound between n-octanol and water at pH 7.4, MW: molecular weight, tPSA: topological polar surface area, CNS MPO: central
nervous system multiparameter optimisation.
K. Amporndanai et al. / EBioMedicine 59 (2020) 102980 5higher polarity of the pyridyl ring that can establish stronger cross-
monomer linking than compound 6 via dipole-diploe interaction
with the main chain of neighbour Asp119 (Fig. 2d) resulting in the
best stabilisation among methylene linker series. Based on an inte-
grated knowledge of the binding mode visualisation in crystallo-
graphic structures, DSF assays and MPO score analysis, we noted that
compounds 9 & 10 from methylene linker series and compounds 12
& 13 from N-aryl series are front runners from this class with excel-
lent DTm and MPO profiles.3.3. In vitro neuroprotection and toxicity of lead compounds in mouse
neuronal cells
A phenotypic screening of ebselen, edaravone and nine lead com-
pounds (1, 2, 5, 6, 9, 10, 11-13) has been undertaken in mouse N2a
neuronal cells transfected with human wild-type and G93A SOD1,
which is the mutant used in representative SOD1-ALS transgenic
mice [27]. The biophysical study of G93A SOD1 revealed that the
mutation at residue 93 destabilises SOD1 via opening b-barrel
Table 2
N-aryl series compounds 11-14with their A4VC6S SOD1 dimer stability (DTm), MPO score and each physicochemical parameter that contributes to the over-
all score. A traffic light system was employed to demonstrate each value contribution; Green  good/desirable; Amber  ok; Red  poor/undesirable. ClogP:
calculated logarithm of partition coefficient of a compound between n-octanol and water, ClogD: calculated logarithm of distribution coefficient of a com-
pound between n-octanol and water at pH 7.4, MW: molecular weight, tPSA: topological polar surface area, CNS MPO: central nervous system multi-param-
eter optimisation.
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trometry demonstrated that G93A SOD1 has wild-type-like dimer
interaction. Ebselen increased dimer affinity of wild-type by only 2
fold and G93A SOD1 by just over 5 fold in contrast to the 60 fold
increase for A4V [17]. G93A SOD1 was not used as a model to find
dimer stabilising compound via DSF assay. However, in vitro screen
against neuronal cells expressing G93A SOD1 is still critical for verify-
ing neuroprotective activity of compound prior to in vivo experiment
in SOD1-ALS transgenic mice. All compounds were dosed to N2a cells
at the concentrations of 0.1, 1 and 10 mM and then incubated for two
days before measuring cell viability by MTS assay. Relative cell viabil-
ity of each compound at different concentrations are presented in bar
charts in Fig. 3. We used N2a cells expressing wild-type SOD1 as a
control, because wild-type SOD1 does not induce any obvious dam-
age to cells in this experimental condition [35]. We found that trans-
genic N2a cells expressing G93A SOD1 used as negative control have
significantly lower cell viability, about 62% of wild-type SOD1. Fur-
thermore, edaravone which is an approved ALS drug, was used as
positive control in this screen. With the aim of producing an ALS drug
that can stabilise SOD1, a good compound should redeem G93A
SOD1 transfected cell using a lower dose than edaravone.
Most of the ebselen-based compounds seem to be toxic to N2a cell
at 10mM resulting in lower viability than the negative control. Fortu-
nately, many compounds performed good neuroprotective effect at
0.1 and 1 mM. Compounds 9 and 10 appeared to be the most potent
compounds recovering G93A SOD1-transfected cell to the same level
of wild-type cell even at 10mM (indicating better overall safety
index) and could be selected for in vivo experiments. In contrast,
compounds 12 and 13, which possess excellent DTm values, gave
poor neuroprotection at 1 and 10mM.
Incorporation of the carbonyl morpholine group in compounds 12
and 13 might not only enhance stabilisation of SOD1 dimer, but also
stimulate unexpected cytotoxicity. To verify this concept, cell viabil-
ity of N2a cells in ebselen, compounds 6 and 12 at seven concentra-
tions were measured and median lethal doses (LC50) were calculated.
The results in Fig. S5a show that LC50 of compound 12 (17.6 mM) wasabout half of ebselen (32.8 mM), indicating that compound 12 is
more cytotoxic than ebselen. On the other hand, compound 6 had
LC50 at 71.0 mM that is considered as a safer compound than ebselen.
To gain further insight, we assayed compound 6 at 0.1 mM in N2a
cells expressing other SOD1 mutants- A4V, G37R, G85R (Fig. S5b).
This compound was found to be effective not only in G93A SOD1-
transfected cell, but also enhanced cell survival in other ALS SOD1
mutants, including A4V. This result suggests that ebselen-based com-
pounds are also applicable and beneficial for neuronal cells express-
ing other ALS-linked SOD1 mutants.
3.4. In-vivo experiments: impact of Ebselen in G93A SOD1 transgenic
mice
In preparation for selecting potential candidates to progress into
the clinical phase, we have set up in vivo trial of compounds using
G93A SOD1 transgenic mice. The first set of experiments have been
completed using ebselen to give an indication of the potential in-vivo
efficacy of this scaffold and identify potential lead compounds. The
mice were fed by powder food mixed with/without 0.016% w/w ebse-
len (estimated dose: 24 mg/kg) from day 70 till end-stage. Survival
experiments were performed to determine disease onset and mouse
survival time, shown in Fig. 4. We found that ebselen significantly
delayed the disease onset of ALS in mice (control: 118.9§5.8 days
and ebselen: 128.0§5.2 days shown as mean§SD). However, mean
survival time of transgenic mice was extended only marginally (con-
trol: 153.1§11.4 days and ebselen: 156.6§11.4 days, mean§SD). The
body weights, the rotarod performance, and the clasping signs, which
are the markers used to evaluate disease progression, were not
affected by ebselen (Fig. S6).
4. Discussion
SOD1 is a ubiquitously expressed protein enriched in nervous sys-
tem. Genetic mutations throughout the SOD1 structure, including
A4V substitution, result in protein destabilisation and cytosolic
Table 3
Crystallographic data collection and refinement statistics of A4V SOD1 with bound compound crystals in P21 space group.
Parameter/ligand Ebselen Compound 1 Compound 2 Compound 3 Compound 5
Data collection
Space group P21 P21 P21 P21 P21
Cell dimensions
a, b, c (A

) 38.95, 67.72, 50.65 38.34, 67.95, 50.46 38.61, 68.29, 50.90 37.33, 68.26, 50.71 38.50, 68.32, 51.32
a, b, g (°) 90.00, 106.40, 90.00 90.00, 105.54, 90.00 90.00, 105.76, 90.00 90.00, 105.07, 90.00 90.00, 106.36, 90.00
Resolution (A

)* 39.481.45 (1.471.45) 48.611.35 (1.371.35) 39.801.95 (2.001.95) 32.461.60 (1.631.60) 36.941.55 (1.581.55)
Rmerge* 4.6 (58.5) 4.8 (40.1) 6.5 (34.4) 7.1 (39.8) 4.2 (27.9)
I/sI* 10.6 (1.8) 9.7 (1.8) 7.4 (2.3) 6.9 (2.0) 11.6 (2.0)
CC1/2 (%)* 0.998 (0.686) 0.997 (0.795) 0.985 (0.538) 0.991 (0.774) 0.998 (0.887)
Completeness (%)* 99.3 (99.8) 99.8 (99.4) 99.7 (98.9) 100.0 (99.8) 99.8 (99.6)
Redundancy* 3.3 (3.4) 3.2 (2.6) 3.1 (3.2) 3.4 (3.4) 3.2 (3.3)
Refinement
No. reflections 44,730 54,619 18,610 33,188 37,031
Rwork/Rfree 15.28/18.82 20.79/23.21 22.10/24.20 18.58/21.71 18.91/20.77
No. atoms
Protein 2237 2291 2200 2289 2291
Ligand/ion Water 32/34 195 34/19 229 36/14 95 57/22 223 36/6 166
B-factors
Protein 22.06 20.27 31.69 26.15 22.24
Ligand/ion 43.20/ 49.69 43.12/ 36.12 62.32/ 55.43 29.95/ 31.28 38.60/ 23.81




) 0.0181 0.0151 0.0117 0.0118 0.0131
Bond angles (°) 1.912 1.8737 1.608 1.643 1.746
PDB code 6Z4G 6Z4O 6Z4H 6Z4I 6Z4J
Parameter/ligand Compound 6 Compound 9 Compound 10 Compound 13
Data collection
Space group P21 P21 P21 P21
Cell dimensions
a, b, c (A

) 38.24, 68.32, 50.98 38.93, 67.49, 50.78 38.41, 68.00, 50.90 39.07, 68.09, 50.86
a, b, g (°) 90.00, 106.17, 90.00 90.00, 106.12, 90.00 90.00, 106.24, 90.00 90.00, 106.87, 90.00
Resolution (A

)* 34.331.45 (1.471.45) 34.691.50 (1.531.50) 36.881.55 (1.581.55) 39.601.25 (1.271.25)
Rmerge* 3.1 (56.1) 5.8 (46.5) 6.5 (42.2) 7.8 (56.2)
I/sI* 13.3 (1.4) 9.7 (1.9) 8.5 (2.0) 8.0 (2.2)
CC1/2 (%)* 0.999 (0.609) 0.994 (0.745) 0.992 (0.798) 0.988 (0.524)
Completeness (%)* 99.4 (99.4) 95.2 (82.0) 99.7 (99.7) 99.3 (99.3)
Redundancy* 3.3 (3.0) 3.5 (3.1) 3.1 (3.1) 3.3 (3.2)
Refinement
No. reflections 44,648 40,405 36,517 66,385
Rwork/Rfree 19.47/20.92 18.66/20.62 19.49/20.78 17.76/19.12
No. atoms
Protein 2244 2261 2286 2260
Ligand/ion Water 38/6 232 34/19 232 38/11 190 50/29 288
B-factors
Protein 21.59 19.68 21.86 13.18
Ligand/ion 29.89/ 23.64 29.57/ 28.64 36.52/ 34.53 22.21/ 26.92




) 0.0147 0.0115 0.0103 0.0155
Bond angles (°) 1.747 1.749 1.682 1.901
PDB Code 6Z4K 6Z4L 6Z4M 6Z3V
* Values in parenthesis denote the highest resolution shell.
K. Amporndanai et al. / EBioMedicine 59 (2020) 102980 7aggregation leading to neuron death [5]. A4V mutation causes steric
clashes with neighbouring residues, altering dimer interface and dis-
turbing protein dimer stability and affinity [9,39,40]. Thus, prevent-
ing monomerisation of SOD1 is considered an important feature of
novel therapeutic agent that delays SOD1-related ALS progression.
Cys111 in SOD1 is amenable to be oxidised that is considered to pro-
mote monomerisation and inclusion formation [18,41]. As such it has
become a focus for small molecule intervention for stabilising SOD1
dimer and also reducing the chance of oxidative modification
[1517].
Ebselen has been proven as a potential template with good ability
to increase the affinity of A4V SOD1 dimer formation [17] and ther-
mal stability of A4VC6S SOD1 [26] when bound with cys111. In this
study, we generated a group of organoselenium compounds using
benzoisoselenazolone ring of ebselen incorporated withfunctionalised methylene linker and N-aryl moieties. The new mole-
cules were designed as CNS-accessible compounds with drug-like-
ness profiles on the basis of high scores of MPO from predicted
physiochemical properties (Tables 1&2) before evaluating their per-
formance against A4VC6S SOD1 in DSF assay. Some compounds in
methylene linker series (compounds 1, 3, 6, 9, 10 and 14) and N-aryl
series (compounds 12 &13), which exhibited SOD1 stabilisation with
large positive DTm values at the same degree or better than ebselen,
were listed as potent candidates. Crystallographic investigation of
A4V SOD1 bound with those candidates revealed binding poses at
cys111 and rationalised how each chemical moiety interacts with
SOD1 enhancing dimeric contact. Identical to the parent drug ebse-
len, N-aryl compound 13 localises parallel to loop VI allowing p-p
stacking interaction opposing the same molecule at another mono-
mer. The carbonyl morpholine group and fluorine atom in compound
Fig. 1. The crystal structures of A4V SOD1 in P21 space group with bound compounds. a Cartoon representation of A4V SOD1 dimer with ligands. The ligands (yellow sticks in red
box) bind each monomer (purple and blue) at cys111, located at the dimer interface. Electron density (2Fo-Fc) maps of b ebselen and c-j compounds 1, 2, 3, 5, 6, 9, 10 and 13 are con-
toured at 1s in green mesh. The 2Fo-Fc map of water molecules (red spheres) and cys111 residues (purple and blue sticks) are contoured at 1s in grey mesh. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
8 K. Amporndanai et al. / EBioMedicine 59 (2020) 10298013 can establish water bridging with SOD1 residues at dimer inter-
face through hydrogen bonds that results in fantastic thermal stabil-
ity. In contrast to N-aryl series, the compounds with methylene
linker have binding mode almost perpendicular to N-aryl compounds
due to their higher flexibility. They reinforce dimer stability by pick-
ing up interactions with Thr2 and Ile151 of N- and C-termini of SOD1,
respectively. This point could be utilised by growing small functional
groups at benzyl tail to develop additional contacts. Incorporation of
para-methoxy group in compound 3 seems to be more beneficial
than halogen atoms according to significant greater DTm because its
size and position may perfectly fitt the space between Thr2 and
Ile151. Nevertheless, meta-methoxy group results in distinct poses of
benzyl tail in A4V SOD1 dimer. Interestingly, crystal structures of
compounds 6 and 9 shows that benzyl tail of one ligand establish
cross-monomer linking with Asp109 of opposite monomer. This
seems to result in better stabilisation especially in compound 8 pro-
motes thermal stability above other compounds in the same series.
Moreover, chemical modification using a pyridyl ring as a more polar
aromatic tail in compound 9 confers exceptional values of MPO
scores and physicochemical parameters that opens opportunity to
explore more potential compounds based on this moiety. We modi-
fied compound 9 by incorporating with a para-methoxy group (com-
pound 10) or carbonyl morpholine (compound 14). Both compounds
certainly gave the highest rank in MPO scores and other parameters
and effective A4V SOD1 stabilisation which may be potential neuro-
protective agents with expected good drug-likeness.
We tested the neuroprotective activity against G93A SOD1
expressing mouse neuronal cells of potent candidates which were
selected by exceptional DTm, MPO and physiochemical parameters
scores. The parent ebselen can redeem G93A SOD1 neuron cellviability almost up to wild-type level in much lower dose than the
licensed drug edaravone, which implies better potency for this class
of compounds. We can see potentially high survival level of neuronal
cells after treatment with low concentrations at 0.1 and 1 mM of all
methylene linker compounds. However, most compounds in this
series and ebselen show lethality to neuron cells at concentration of
10 mM. Compounds 9 and 10 containing a pyridyl ring seems to be
the most promising candidates among tested compounds with the
strongest in vitro neuroprotective activity and much smaller loss of
neuron cells at high dose. Thus, the methylene linker compounds
with pyridyl group should be the focus for further development and
optimisation of safe neuroprotective compounds, but para-methoxy
group appears not essential to improve healing effect in mouse neu-
ronal cells. Carbonyl morpholine derivatives (compounds 12, 13),
which are the most promising candidates due to their excellent DTm
and predicted MPO scores, exhibit the poorest level of neuroprotec-
tion among other candidates. This observation suggests carbonyl
morpholine group displays non-selective binding to other endoge-
nous targets leading to neuron cell death.
In addition to in vitro neuroprotective performance of our com-
pounds, transgenic mice expressing G93A SOD1, a frequently used
SOD1-ALS mouse model, were treated orally with ebselen and moni-
tored for their motor activities and survival times. Even though ebse-
len does not extend total lifetime of experimental mice appreciably
compared to the controls, we observed a delayed disease onset in
ebselen-treated G93A mice (>10 days). This confirms that ebselen
can be absorbed in digestive tract and replicate its neuroprotective
effect in animal model. Ebselen has a reducing activity to suppress
oxidative stress that may contribute to neuroprotective effect [25].
However, our compounds, apart from their reducing potential,
Fig. 2. Superimposed and individual crystal structures of A4V SOD1 bound with compounds. a Ebselen (pink) and compound 13 (yellow). b Compounds 2 (cyan) and 5 (pink). c
Compounds 3 (cyan) and 6 (pink). d Compounds 9 (cyan) and 10 (pink). Surrounding amino acid residues of each monomers are coloured in purple and blue. Waters are represented
as red dots. Hydrogen bonds are illustrated as green dashed lines. The distances between atoms and between aromatic rings are illustrated as yellow and black dashed lines, respec-
tively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
K. Amporndanai et al. / EBioMedicine 59 (2020) 102980 9showed significantly improved neuroprotective activity measured by
our MTS assay. This suggests that the direct interaction with SOD1 is
a key determinant of neuroprotective activity of our new compounds
rather than their reducing activity per se. We propose that com-
pounds 9 and 10 may prove better in the in vivo activities than ebse-
len and result in an increased survival rate of transgenic mice and
thus may have better prospects for clinical trials.
Thus, we have generated two promising series of ebselen-based
compounds for stabilising mutant SOD1 including A4V. We used
DSF assays, MPO scores and predicted physicochemical parameters
to rank lead compounds before measuring neuroprotective effects
in cell-based assays and animal models. The methylene linked
series showed outstanding neuroprotective activities in mouse
neuronal cells, particularly compounds 9 and 10 with a pyridyltail, which can be considered an excellent scaffold for further opti-
misation in drug development programme. However, our N-aryl
compounds with carbonyl morpholine are less selective in spite of
excellent outcomes in DSF assays. These results demonstrate that
DSF assay is a good tool for hit to lead optimisation in this disease
area, but phenotypic cell-based experiments are still required to
evaluate in vitro effectiveness and cytotoxic effects. Apart from
neuroprotection and safety profiles, in vitro and in vivo pharmaco-
kinetic and pharmacodynamics studies of lead compounds should
be addressed to select the most powerful candidates. Here, we
also verified neuroprotective action of ebselen in mouse model
showing effective oral availability and delay in disease onset. Fur-
ther optimisation of this template can be envisaged to improve
drug potency and increase the overall survival time.
Fig. 3. Ebselen-based compounds confer neuroprotection in mouse N2a cells expressing G93A mutant form of SOD1. MTS assays of mouse N2a cells transfected with wild-type
(WT) or G93A SOD1 in the presence of ebselen, ebselen-based compounds, or edaravone at the indicated concentrations. The results with each the ebselen-based compounds are
displayed with colors based on its physicochemical parameters shown in Table 1. Green  good/desirable; Light green  almost good/desirable; Amber  ok; Red  poor/undesir-
able. Relative cell viability levels of WT and G93A SOD1 are shown as blue and black dashed lines, respectively. Asterisks indicate statistically significant protection (p< 0.05) against
G93A SOD1. Averaged cell viability §SEM relative to the one expressing WT SOD1 was plotted. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 4. Onset and survival curves of G93A SOD1 transgenic mice treated with ebselen. a Disease onset curves for ebselen-treated G93A SOD1 mice and control G93A SOD1 mice
(Ebselen: 128.0§5.2 days, Control: 118.9§5.8 days; mean§SD, p = 0.0006 in log-rank test). b Survival curves for ebselen-treated G93A SOD1 mice and control (Ebselen: 156.6§
11.4 days, Control: 153.1§11.4 days; shown as mean§SD, p = 0.3530 in log-rank test). The same numbers of mice were used for onset and survival analysis (control, n=10; ebselen,
n=12). All the mice are female.
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We have established that the new generation of ebselen-based
compounds are potent, multimodal SOD1 pharmacological chaper-
one targeting cysteine 111, restoring the dimer affinity of, say A4V
SOD1 to that of uncompromised wild-type SOD1, prevent the forma-
tion of oligomers/aggregates. This is an important significant mile-
stone in the chemical-assisted manipulation of SOD1 for the
treatment of ALS endorsed by the neuroprotection offered in mouse
N2a neuronal cells transfected with human wild-type and G93A
SOD1. Several of the compounds including ebselen redeemed G93A
SOD1 transfected cells better than the drug Edaravone (approved in
USA in 2017), which has had limited efficacy and acceptance as a
drug worldwide, requiring daily intravenous infusion. In addition to
the in vitro neuroprotective performance, oral treatment with ebse-
len did not extend total lifespan of G93A SOD1 mice, but significantly
delayed a disease onset by >10 days, confirming that ebselen (and by
extension ebselen-based compounds) can be absorbed in digestive
tract and replicate its neuroprotective effect in animal model. In sum-
mary, we have demonstrated outperformance of ebselen and its new
generation of leads over edaravone where the formulations are suit-
able for effective oral administration for a sustained treatment for
ALS.
The ability of our compounds to target a cysteine may extend to
other protein targets such as the main protease (Mpro) of COVID-19
virus whose recent crystallographic studies with inhibitor and the
docking study with ebselen indicates covalent interaction with
Cys145 is the mechanism of its inhibition [42]. This is further sup-
ported by the docking of new ebselen-based compound developed
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